HTH

Zcube, the Zambon Research Venture, in collaboration with HTH announces the 5 Startups Selected for the New Edition of the Open Accelerator (2024) Focused on Women’s Health and Femtech! Check out the selected startups!

🚀 Happy to announce that I’ll be speaking at the MedTech World Conference 2024, taking place in Malta from November 6th to 8th! This will be an incredible opportunity to discuss the latest innovations and trends in MedTech, engage with industry experts, and share our vision with other investors and startups. If you’ll be attending, I’d love to meet and exchange ideas, dealflow and exciting opportunities! #MedTechMalta2024 MedTech World HTH Rodney Moses Dylan Attard MD, MRCSI, MEnt.

HTH has just made a new investment: EpilepsyGTx! EpilepsyGTx is pioneering innovative gene therapies for focal refractory epilepsy with the mission to make patients seizure-free. We are confident that EpilepsyGTx's groundbreaking solutions will make a significant impact, and we are proud to support this outstanding team.

Check this new job position for our partner ZCube!

We are thrilled to announce that Delpor, Inc. , a biopharmaceutical company in our portfolio that utilizes innovative technologies to develop once-yearly therapeutics for chronic conditions, has published today the incredible topline results of its DLP-114 Phase 1b/2a clinical study during which schizophrenia patients (n=28) received treatment for up to one year after a single administration. The clinical study (NCT04418466) was an open-label study in stable schizophrenia patients to evaluate the safety, tolerability, and pharmacokinetics (PK) of switching from oral risperidone to risperidone delivered over 6 to 12 months with the risperidone implant. The study has clearly indicated that DLP-114 has the potential to provide antipsychotic treatment for persons with schizophrenia for up to one year after a single administration. This may represents a major breakthrough as a 6–12-month dosing interval is expected to improve medication adherence which is a major unmet need within mental illness. If approved, Delpor's risperidone implant will be the first once-yearly schizophrenia maintenance therapy 💊 We are extremely proud, congrats Tassos Nicolaou & Delpor, Inc. team Michele G.Marco GullàPierre MORGONDelpor, Inc.Tassos Nicolaou